Inhibitors of bruton's tyrosine kinase

Patent metadata

Field	Value
Publication number	US-9409911-B2
Application number	US-201314073594-A
Country	US
Kind code	B2
Filing date	Nov 6, 2013
Priority date	Sep 22, 2006
Publication date	Aug 9, 2016
Grant date	Aug 9, 2016

Abstract

Disclosed herein are compounds, including compounds having the structure of Formula (A), (B), (C), and (D), as described in further detail herein, that form covalent bonds with Bruton's tyrosine kinase (Btk). Also described are irreversible inhibitors of Btk. Methods for the preparation of the compounds are disclosed. Also disclosed are pharmaceutical compositions that include the compounds. Methods of using the Btk inhibitors are disclosed, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, and inflammatory diseases or conditions.

First claim

What is claimed is:

1. A method of treating a TXK-mediated B-cell malignancy, comprising administering to a patient in need thereof a therapeutically effective amount of a compound that irreversibly inhibits TXK, wherein the compound has the structure of Formula (A):

wherein:
A is N;
R 1 is L 2 -(substituted or unsubstituted heteroaryl), or L 2 -(substituted or unsubstituted aryl), where L 2 is a bond, O, S, —S(═O), —S(═O) 2 , C(═O), -(substituted or unsubstituted C 1 -C 6 alkyl), or -(substituted or unsubstituted C 2 -C 6 alkenyl);
R 2 and R 3 are independently selected from H and lower alkyl;
R 4 is L 3 -X-L 4 -G, wherein,
L 3 is optional, and when present is a bond, optionally substituted or unsubstituted alkyl, optionally substituted or unsubstituted cycloalkyl, optionally substituted or unsubstituted alkenyl, or optionally substituted or unsubstituted alkynyl;
X is optional, and when present is a bond, O, —C(═O), S, —S(═O), —S(═O) 2 , —NH, —NR 9 , —NHC(O), —C(O)NH, —NR 9 C(O), —C(O)NR 9 , —S(═O) 2 NH, —NHS(═O) 2 , —S(═O) 2 NR 9 —, —NR 9 S(═O) 2 , —OC(O)NH—, —NHC(O)O—, —OC(O)NR 9 —, —NR 9 C(O)O—, —CH═NO—, —ON═CH—, —NR 10 C(O)NR 10 —, heteroaryl, aryl, —NR 10 C(═NR 11 )NR 10 —, —NR 10 C(═NR 11 )—, —C(═NR 11 )NR 10 —, —OC(═NR 11 )—, or —C(═NR 11 )O—;
L 4 is optional, and when present is a bond, substituted or unsubstituted alkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, or substituted or unsubstituted heterocycle;
or L 3 , X and L 4 taken together form a nitrogen containing heterocyclic ring;
G is

wherein,
R 6 , R 7 and R 8 are independently selected from among H, lower alkyl or substituted lower alkyl, lower heteroalkyl or substituted lower heteroalkyl, substituted or unsubstituted lower cycloalkyl, and substituted or unsubstituted lower heterocycloalkyl;
R 9 is selected from among H, substituted or unsubstituted lower alkyl, and substituted or unsubstituted lower cycloalkyl;
each R 10 is independently H, substituted or unsubstituted lower alkyl, or substituted or unsubstituted lower cycloalkyl; or
two R 10 groups can together form a 5-, 6-, 7-, or 8-membered heterocyclic ring; or
R 10 and R 11 can together form a 5-, 6-, 7-, or 8-membered heterocyclic ring; or
R 11 is selected from H, —S(═O) 2 R 8 , —S(═O) 2 NH 2 , —C(O)R 8 , —CN, —NO 2 , heteroaryl, and heteroalkyl; or a pharmaceutically acceptable solvate, hydrate, or salt thereof.

2. The method of claim 1 , wherein the compound has the structure:

3. The method of claim 1 , wherein R 1 is L 2 -substituted aryl; and L 2 is a bond.

4. The method of claim 1 , wherein R 2 and R 3 are independently H.

5. The method of claim 1 , wherein the compound of Formula (A) has the structure of Formula (B):

wherein:
Y is alkyl or substituted alkyl, or a 4-, 5-, or 6-membered cycloalkyl ring;
each R a is independently H, halogen, —CF 3 , —CN, —NO 2 , OH, NH 2 , -L a -(substituted or unsubstituted alkyl), -L a -(substituted or unsubstituted alkenyl), -L a -(substituted or unsubstituted heteroaryl), or -L a -(substituted or unsubstituted aryl), wherein L a is a bond, O, S, —S(═O), —S(═O) 2 , NH, C(O), CH 2 , —NHC(O)O, —NHC(O), or —C(O)NH;
G is

wherein,
R 6 , R 7 and R 8 are independently selected from among H, lower alkyl or substituted lower alkyl, lower heteroalkyl or substituted lower heteroalkyl, substituted or unsubstituted lower cycloalkyl, and substituted or unsubstituted lower heterocycloalkyl;
R 12 is H or lower alkyl; or

Y and R 12 taken together form a 4-, 5-, or 6-membered heterocyclic ring; or a pharmaceutically acceptable solvate, hydrate, or salt thereof.

6. The method of claim 5 , wherein Y and R 12 taken together form a 6-membered heterocyclic ring.

7. The method of claim 5 , wherein the compound of Formula (B) has the structure of Formula (C):

wherein:
Y is alkyl or substituted alkyl, or a 4-, 5-, or 6-membered cycloalkyl ring;
R 12 is H or lower alkyl; or
Y and R 12 taken together form a 4-, 5-, or 6-membered heterocyclic ring;
G is

wherein,
R 6 , R 7 and R 8 are independently selected from among H, lower alkyl or substituted lower alkyl, lower heteroalkyl or substituted lower heteroalkyl, substituted or unsubstituted lower cycloalkyl, and substituted or unsubstituted lower heterocycloalkyl; or a pharmaceutically acceptable solvate, hydrate, or salt thereof.

8. The method of claim 7 , wherein Y and R 12 taken together form a 4-, 5-, or 6-membered heterocyclic ring.

9. The method of claim 7 , wherein G is

10. The method of claim 7 , wherein R 6 , R 7 , and R 8 are independently H.

11. A method of treating a B-cell malignancy, comprising administering to a patient in need thereof a therapeutically effective amount of a compound that irreversibly inhibits TXK, wherein the compound has the structure of Formula (D):

wherein
L a is CH 2 , O, NH or S;
Ar is an optionally substituted aromatic carbocycle or an aromatic heterocycle;
Y is an optionally substituted alkyl, heteroalkyl, carbocycle, heterocycle, or combination thereof;
Z is C(O), OC(O), NHC(O), C(S), S(O) x , OS(O) x , or NHS(O) x , where x is 1 or 2; and
R 6 , R 7 , and R 8 are independently selected from H, alkyl, heteroalkyl, carbocycle, and heterocycle, or combinations thereof.

12. The method of claim 11 , wherein La is O, Ar is an aromatic carbocycle, Y is heterocycle, Z is C(O), and R 6 , R 7 , and R 8 are independently H.

13. A method of inhibiting TXK in a patient having a B-cell malignancy, comprising administering to a patient in need thereof a therapeutically effective amount of a compound that irreversibly inhibits TXK, wherein the compound has the structure of Formula (A):

wherein:
A is N;
R 1 is L 2 -(substituted or unsubstituted heteroaryl), or L 2 -(substituted or unsubstituted aryl),
where L 2 is a bond, O, S, —S(═O), —S(═O) 2 , C(═O), -(substituted or unsubstituted C 1 -C 6 alkyl), or -(substituted or unsubstituted C 2 -C 6 alkenyl);
R 2 and R 3 are independently selected from H and lower alkyl;
R 4 is L 3 -X-L 4 -G, wherein,
L 3 is optional, and when present is a bond, optionally substituted or unsubstituted alkyl, optionally substituted or unsubstituted cycloalkyl, optionally substituted or unsubstituted alkenyl, or optionally substituted or unsubstituted alkynyl;
X is optional, and when present is a bond, O, —C(═O), S, —S(═O), —S(═O) 2 , —NH, —NR 9 , —NHC(O), —C(O)NH, —NR 9 C(O), —C(O)

Assignees

• Pharmacyclics Llc

Inventors

• Honigberg Lee
• Verner Erik
• Pan Zhengying

Classifications

• A61P7/02

  Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors · CPC title

• A61P43/00

  Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00 · CPC title

• A61P37/02

  Immunomodulators · CPC title

• A61P35/02

  specific for leukemia · CPC title

• A61P37/08

  Antiallergic agents (antiasthmatic agents A61P11/06; ophthalmic antiallergics A61P27/14) · CPC title